| The purpose of this retrospective, observational study was to investigate the clinical use of pertuzumab in a population of patients with HER2-positive mBC treated in a real-world community oncology practice setting. |
| We found that most patients were treated with pertuzumab, trastuzumab, and a taxane in the first-line setting. |
| Our results confirmed the clinical safety and PFS of pertuzumab as first-line therapy for patients with HER2-positive mBC in the community treatment setting. |
| The use of pertuzumab in this setting was consistent with the NCCN guidelines (2012) and, for the most part, with the FDA-approved Perjeta® (pertuzumab) prescribing information. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.